Reason for request
Inclusion on list of products for hospital use.
Clinical Benefit
| Substantial |
The actual benefit of ACTILYSE 2 mg is substantial. |
Clinical Added Value
| minor |
ACTILYSE 2 mg provides a minor improvement in actual benefit (IAB IV) in terms of efficacy in comparison with ACTOSOLV UROKINASE. |
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
QBa6MUu3Rdg37tV2
Listen
